{"id":{"repo_id":"mcmaster","oai_identifier":"oai:macsphere.mcmaster.ca:11375/12411"},"canonical_url":"https://search.ndltd.org/etd/mcmaster/oai:macsphere.mcmaster.ca:11375/12411","repository":{"repo_id":"mcmaster","name":"McMaster University","base_url":"https://macsphere.mcmaster.ca/server/oai/request"},"display":{"title":"Fusing the C-terminal tridecapeptide of hirudin to α1-proteinase inhibitor M358R accelerates its rate of thrombin inhibition","abstract":"<p>The serpin α-1 proteinase inhibitor (API) normally only impacts the coagulation cascade through its ability to inactivate factor XIa. However, the point mutation (Met to Arg) at position 358 results in a potent thrombin inhibitor, API M358R. This mutation also enhances this serpin’s ability to inhibit the anticoagulant protein, activated protein C (APC) and hence this property limits its therapeutic potential. As a result, various modifications to this protein have been engineered in order to enhance its specificity towards thrombin. Previously, the Heparin Cofactor II (HCII) N-terminal tail, HCII 1-75, which binds exosite 1 of thrombin, was tethered to the N-terminus of API M358R, creating HAPI M358R. Although this change did not alter anti-APC activity, it did augment the anti-thrombin activity of API M358R. In addition, further changes in the reactive center loop, the region that interacts with the thrombin active site, resulted in a significant reduction in APC activity while maintaining antithrombotic activity similar to HAPI M358R; this variant was termed HAPI RCL5.</p> <p>Preliminary experiments were performed with the C-terminal tridecapeptide of Hirudin Variant 3 (HV3) to determine its exosite 1 binding capacity compared to HCII 1-75. Three different variants of this peptide were tested: one with a hexahistidine tag (H<sub>6</sub>HV3<sub>54-66</sub>), another that also had a hexa-glycine C-terminal addition (H<sub>6</sub>HV3<sub>54-66</sub>G<sub>6</sub>) and a third without either addition. All were found to bind exosite 1 with a greater affinity than HCII 1-75. Thus, the H<sub>6</sub>HV3<sub>54-66</sub>G<sub>6 </sub>peptide was fused to API M358R and API RCL5 in hopes of creating an inhibitor with heightened specificity compared to HAPI M358R and HAPI RCL5, respectively.</p> <p>HV3API M358R and HV3API RCL5 were expressed in a bacterial system and purified by nickel-chelate and ion exchange chromatography. Second order rate constants for the inhibition of thrombin and APC by the API variants and fusion proteins were determined. The K<sub>2</sub> values for α-thrombin inhibition ranged from 186 M<sup>-1</sup>min<sup>-1</sup> to 22 M<sup>-1</sup>min<sup>-1</sup> with an order of inhibitory potency observed as follows: HAPI M358R > HAPI RCL5 > HV3API M358R > HV3API RCL5>API RCL5 > API M358R.</p> <p>The ability of recombinant chimeric serpins to bind thrombin exosite 1 in a manner independent of RCL-thrombin active site interactions was also investigated through competitive inhibition of the binding of active site-inhibited thrombin to immobilized HCII 1-75. It was found that the order of exosite 1 binding affinity was HV3API RCL5 > H<sub>6</sub>HV3<sub>54-66</sub>G<sub>6</sub>> HCII 1-75 > HAPI RCL5. Our results indicate that fusing the C-terminal tridecapeptide of HV3 to API variants enhanced their ability to inhibit thrombin, but to a lesser extent than fusing the N-terminal 75 residues of HCII. This finding likely reflects a requirement for the exosite 1-binding motif of the fusion protein to bind exosite 1 in a way that allows for subsequent optimal active site attack on the RCL by the serpin moiety of the fusion protein. In general, this work provides a second novel example of how the activity of a thrombin-inhibitory serpin can be enhanced by fusion to an exosite-1 binding motif.</p>","abstract_html":"&lt;p&gt;The serpin α-1 proteinase inhibitor (API) normally only impacts the coagulation cascade through its ability to inactivate factor XIa. However, the point mutation (Met to Arg) at position 358 results in a potent thrombin inhibitor, API M358R. This mutation also enhances this serpin’s ability to inhibit the anticoagulant protein, activated protein C (APC) and hence this property limits its therapeutic potential. As a result, various modifications to this protein have been engineered in order to enhance its specificity towards thrombin. Previously, the Heparin Cofactor II (HCII) N-terminal tail, HCII 1-75, which binds exosite 1 of thrombin, was tethered to the N-terminus of API M358R, creating HAPI M358R. Although this change did not alter anti-APC activity, it did augment the anti-thrombin activity of API M358R. In addition, further changes in the reactive center loop, the region that interacts with the thrombin active site, resulted in a significant reduction in APC activity while maintaining antithrombotic activity similar to HAPI M358R; this variant was termed HAPI RCL5.&lt;/p&gt; &lt;p&gt;Preliminary experiments were performed with the C-terminal tridecapeptide of Hirudin Variant 3 (HV3) to determine its exosite 1 binding capacity compared to HCII 1-75. Three different variants of this peptide were tested: one with a hexahistidine tag (H&lt;sub&gt;6&lt;/sub&gt;HV3&lt;sub&gt;54-66&lt;/sub&gt;), another that also had a hexa-glycine C-terminal addition (H&lt;sub&gt;6&lt;/sub&gt;HV3&lt;sub&gt;54-66&lt;/sub&gt;G&lt;sub&gt;6&lt;/sub&gt;) and a third without either addition. All were found to bind exosite 1 with a greater affinity than HCII 1-75. Thus, the H&lt;sub&gt;6&lt;/sub&gt;HV3&lt;sub&gt;54-66&lt;/sub&gt;G&lt;sub&gt;6 &lt;/sub&gt;peptide was fused to API M358R and API RCL5 in hopes of creating an inhibitor with heightened specificity compared to HAPI M358R and HAPI RCL5, respectively.&lt;/p&gt; &lt;p&gt;HV3API M358R and HV3API RCL5 were expressed in a bacterial system and purified by nickel-chelate and ion exchange chromatography. Second order rate constants for the inhibition of thrombin and APC by the API variants and fusion proteins were determined. The K&lt;sub&gt;2&lt;/sub&gt; values for α-thrombin inhibition ranged from 186 M&lt;sup&gt;-1&lt;/sup&gt;min&lt;sup&gt;-1&lt;/sup&gt; to 22 M&lt;sup&gt;-1&lt;/sup&gt;min&lt;sup&gt;-1&lt;/sup&gt; with an order of inhibitory potency observed as follows: HAPI M358R &gt; HAPI RCL5 &gt; HV3API M358R &gt; HV3API RCL5&gt;API RCL5 &gt; API M358R.&lt;/p&gt; &lt;p&gt;The ability of recombinant chimeric serpins to bind thrombin exosite 1 in a manner independent of RCL-thrombin active site interactions was also investigated through competitive inhibition of the binding of active site-inhibited thrombin to immobilized HCII 1-75. It was found that the order of exosite 1 binding affinity was HV3API RCL5 &gt; H&lt;sub&gt;6&lt;/sub&gt;HV3&lt;sub&gt;54-66&lt;/sub&gt;G&lt;sub&gt;6&lt;/sub&gt;&gt; HCII 1-75 &gt; HAPI RCL5. Our results indicate that fusing the C-terminal tridecapeptide of HV3 to API variants enhanced their ability to inhibit thrombin, but to a lesser extent than fusing the N-terminal 75 residues of HCII. This finding likely reflects a requirement for the exosite 1-binding motif of the fusion protein to bind exosite 1 in a way that allows for subsequent optimal active site attack on the RCL by the serpin moiety of the fusion protein. In general, this work provides a second novel example of how the activity of a thrombin-inhibitory serpin can be enhanced by fusion to an exosite-1 binding motif.&lt;/p&gt;","abstract_has_math":false,"creators":["Roddick, Leigh Ann C."],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":"Medical Sciences","school":null,"contributors":[],"advisors":["Sheffield, Bill","Jeffrey Weitz, Patricia Liaw"],"committee_chairs":[],"committee_members":[],"year":2012,"date_issued":"2012-10","date_published":"2012-10","updated_at":"2026-11-18T19:31:08Z","subjects":["blood","coagulation","anticoagulants","serpins","hirudin","Medical Biochemistry","Medical Molecular Biology","Other Medicine and Health Sciences"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://doi.org/10.71548/9232"],"render_values":[{"text":"https://doi.org/10.71548/9232","href":"https://doi.org/10.71548/9232","code":true}]},{"key":"dc:identifier.other","label":"Dc Identifier Other","values":["opendissertations/7300","8336","3268601"],"render_values":[{"text":"opendissertations/7300","href":null,"code":true},{"text":"8336","href":null,"code":true},{"text":"3268601","href":null,"code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/11375/12411","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"http://hdl.handle.net/11375/12411","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://macsphere.mcmaster.ca/server/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Amacsphere.mcmaster.ca%3A11375%2F12411","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Sheffield, Bill","Jeffrey Weitz, Patricia Liaw"]},{"key":"dc:contributor.department","label":"Department","values":["Medical Sciences"]},{"key":"dc:creator","label":"Author","values":["Roddick, Leigh Ann C."]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2014-06-18T16:59:31Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2014-06-18T16:59:31Z"]},{"key":"dc:date.created","label":"Dc Date Created","values":["2012-08-27"]},{"key":"dc:date.issued","label":"Date","values":["2012-10"]},{"key":"dc:type","label":"Dc Type","values":["thesis"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["blood","coagulation","anticoagulants","serpins","hirudin","Medical Biochemistry","Medical Molecular Biology","Other Medicine and Health Sciences"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.other","label":"Dc Identifier Other","values":["opendissertations/7300","8336","3268601"]},{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://hdl.handle.net/11375/12411","https://doi.org/10.71548/9232"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["<p>The serpin α-1 proteinase inhibitor (API) normally only impacts the coagulation cascade through its ability to inactivate factor XIa. However, the point mutation (Met to Arg) at position 358 results in a potent thrombin inhibitor, API M358R. This mutation also enhances this serpin’s ability to inhibit the anticoagulant protein, activated protein C (APC) and hence this property limits its therapeutic potential. As a result, various modifications to this protein have been engineered in order to enhance its specificity towards thrombin. Previously, the Heparin Cofactor II (HCII) N-terminal tail, HCII 1-75, which binds exosite 1 of thrombin, was tethered to the N-terminus of API M358R, creating HAPI M358R. Although this change did not alter anti-APC activity, it did augment the anti-thrombin activity of API M358R. In addition, further changes in the reactive center loop, the region that interacts with the thrombin active site, resulted in a significant reduction in APC activity while maintaining antithrombotic activity similar to HAPI M358R; this variant was termed HAPI RCL5.</p> <p>Preliminary experiments were performed with the C-terminal tridecapeptide of Hirudin Variant 3 (HV3) to determine its exosite 1 binding capacity compared to HCII 1-75. Three different variants of this peptide were tested: one with a hexahistidine tag (H<sub>6</sub>HV3<sub>54-66</sub>), another that also had a hexa-glycine C-terminal addition (H<sub>6</sub>HV3<sub>54-66</sub>G<sub>6</sub>) and a third without either addition. All were found to bind exosite 1 with a greater affinity than HCII 1-75. Thus, the H<sub>6</sub>HV3<sub>54-66</sub>G<sub>6 </sub>peptide was fused to API M358R and API RCL5 in hopes of creating an inhibitor with heightened specificity compared to HAPI M358R and HAPI RCL5, respectively.</p> <p>HV3API M358R and HV3API RCL5 were expressed in a bacterial system and purified by nickel-chelate and ion exchange chromatography. Second order rate constants for the inhibition of thrombin and APC by the API variants and fusion proteins were determined. The K<sub>2</sub> values for α-thrombin inhibition ranged from 186 M<sup>-1</sup>min<sup>-1</sup> to 22 M<sup>-1</sup>min<sup>-1</sup> with an order of inhibitory potency observed as follows: HAPI M358R > HAPI RCL5 > HV3API M358R > HV3API RCL5>API RCL5 > API M358R.</p> <p>The ability of recombinant chimeric serpins to bind thrombin exosite 1 in a manner independent of RCL-thrombin active site interactions was also investigated through competitive inhibition of the binding of active site-inhibited thrombin to immobilized HCII 1-75. It was found that the order of exosite 1 binding affinity was HV3API RCL5 > H<sub>6</sub>HV3<sub>54-66</sub>G<sub>6</sub>> HCII 1-75 > HAPI RCL5. Our results indicate that fusing the C-terminal tridecapeptide of HV3 to API variants enhanced their ability to inhibit thrombin, but to a lesser extent than fusing the N-terminal 75 residues of HCII. This finding likely reflects a requirement for the exosite 1-binding motif of the fusion protein to bind exosite 1 in a way that allows for subsequent optimal active site attack on the RCL by the serpin moiety of the fusion protein. In general, this work provides a second novel example of how the activity of a thrombin-inhibitory serpin can be enhanced by fusion to an exosite-1 binding motif.</p>"]},{"key":"dc:description.degree","label":"Dc Description Degree","values":["Master of Health Sciences (MSc)"]},{"key":"dc:title","label":"Title","values":["Fusing the C-terminal tridecapeptide of hirudin to α1-proteinase inhibitor M358R accelerates its rate of thrombin inhibition"]},{"key":"others:access_status","label":"Others Access Status","values":["open.access"]}]}],"canonical_facts":{"dc:contributor.advisor":["Sheffield, Bill","Jeffrey Weitz, Patricia Liaw"],"dc:contributor.department":["Medical Sciences"],"dc:creator":["Roddick, Leigh Ann C."],"dc:date.accessioned":["2014-06-18T16:59:31Z"],"dc:date.available":["2014-06-18T16:59:31Z"],"dc:date.created":["2012-08-27"],"dc:date.issued":["2012-10"],"dc:description.abstract":["<p>The serpin α-1 proteinase inhibitor (API) normally only impacts the coagulation cascade through its ability to inactivate factor XIa. However, the point mutation (Met to Arg) at position 358 results in a potent thrombin inhibitor, API M358R. This mutation also enhances this serpin’s ability to inhibit the anticoagulant protein, activated protein C (APC) and hence this property limits its therapeutic potential. As a result, various modifications to this protein have been engineered in order to enhance its specificity towards thrombin. Previously, the Heparin Cofactor II (HCII) N-terminal tail, HCII 1-75, which binds exosite 1 of thrombin, was tethered to the N-terminus of API M358R, creating HAPI M358R. Although this change did not alter anti-APC activity, it did augment the anti-thrombin activity of API M358R. In addition, further changes in the reactive center loop, the region that interacts with the thrombin active site, resulted in a significant reduction in APC activity while maintaining antithrombotic activity similar to HAPI M358R; this variant was termed HAPI RCL5.</p> <p>Preliminary experiments were performed with the C-terminal tridecapeptide of Hirudin Variant 3 (HV3) to determine its exosite 1 binding capacity compared to HCII 1-75. Three different variants of this peptide were tested: one with a hexahistidine tag (H<sub>6</sub>HV3<sub>54-66</sub>), another that also had a hexa-glycine C-terminal addition (H<sub>6</sub>HV3<sub>54-66</sub>G<sub>6</sub>) and a third without either addition. All were found to bind exosite 1 with a greater affinity than HCII 1-75. Thus, the H<sub>6</sub>HV3<sub>54-66</sub>G<sub>6 </sub>peptide was fused to API M358R and API RCL5 in hopes of creating an inhibitor with heightened specificity compared to HAPI M358R and HAPI RCL5, respectively.</p> <p>HV3API M358R and HV3API RCL5 were expressed in a bacterial system and purified by nickel-chelate and ion exchange chromatography. Second order rate constants for the inhibition of thrombin and APC by the API variants and fusion proteins were determined. The K<sub>2</sub> values for α-thrombin inhibition ranged from 186 M<sup>-1</sup>min<sup>-1</sup> to 22 M<sup>-1</sup>min<sup>-1</sup> with an order of inhibitory potency observed as follows: HAPI M358R > HAPI RCL5 > HV3API M358R > HV3API RCL5>API RCL5 > API M358R.</p> <p>The ability of recombinant chimeric serpins to bind thrombin exosite 1 in a manner independent of RCL-thrombin active site interactions was also investigated through competitive inhibition of the binding of active site-inhibited thrombin to immobilized HCII 1-75. It was found that the order of exosite 1 binding affinity was HV3API RCL5 > H<sub>6</sub>HV3<sub>54-66</sub>G<sub>6</sub>> HCII 1-75 > HAPI RCL5. Our results indicate that fusing the C-terminal tridecapeptide of HV3 to API variants enhanced their ability to inhibit thrombin, but to a lesser extent than fusing the N-terminal 75 residues of HCII. This finding likely reflects a requirement for the exosite 1-binding motif of the fusion protein to bind exosite 1 in a way that allows for subsequent optimal active site attack on the RCL by the serpin moiety of the fusion protein. In general, this work provides a second novel example of how the activity of a thrombin-inhibitory serpin can be enhanced by fusion to an exosite-1 binding motif.</p>"],"dc:description.degree":["Master of Health Sciences (MSc)"],"dc:identifier.other":["opendissertations/7300","8336","3268601"],"dc:identifier.uri":["http://hdl.handle.net/11375/12411","https://doi.org/10.71548/9232"],"dc:subject":["blood","coagulation","anticoagulants","serpins","hirudin","Medical Biochemistry","Medical Molecular Biology","Other Medicine and Health Sciences"],"dc:title":["Fusing the C-terminal tridecapeptide of hirudin to α1-proteinase inhibitor M358R accelerates its rate of thrombin inhibition"],"dc:type":["thesis"],"others:access_status":["open.access"]},"updated_at":"2026-11-18T19:31:08Z"}